Equities research analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to post sales of $8.84 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Stemline Therapeutics’ earnings, with the lowest sales estimate coming in at $5.55 million and the highest estimate coming in at $11.75 million. Stemline Therapeutics posted sales of $500,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 1,668%. The business is expected to report its next quarterly earnings report on Thursday, August 8th.

According to Zacks, analysts expect that Stemline Therapeutics will report full year sales of $41.46 million for the current year, with estimates ranging from $23.80 million to $54.38 million. For the next fiscal year, analysts expect that the company will report sales of $134.32 million, with estimates ranging from $87.36 million to $207.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million during the quarter, compared to analysts’ expectations of $2.61 million.

Several research firms recently weighed in on STML. Wedbush reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Global Blood Therapeutics in a research note on Monday, May 13th. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 4th. ValuEngine upgraded shares of Vermillion from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Zacks Investment Research cut shares of ZEALAND PHARMA/S from a “buy” rating to a “hold” rating in a report on Saturday. Finally, HC Wainwright set a $35.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a report on Thursday, June 20th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Stemline Therapeutics presently has an average rating of “Buy” and a consensus price target of $23.50.

In other news, CEO Ivan Bergstein sold 10,822 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $15.49, for a total transaction of $167,632.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kenneth Hoberman sold 9,107 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $15.49, for a total transaction of $141,067.43. The disclosure for this sale can be found here. In the last three months, insiders have sold 149,177 shares of company stock valued at $2,236,377. Company insiders own 13.10% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Stemline Therapeutics during the 2nd quarter worth about $67,000. Rhenman & Partners Asset Management AB bought a new stake in shares of Stemline Therapeutics during the 2nd quarter valued at $7,568,000. Metropolitan Life Insurance Co NY boosted its holdings in shares of Stemline Therapeutics by 56.7% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 13,358 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 4,835 shares in the last quarter. MetLife Investment Advisors LLC boosted its holdings in shares of Stemline Therapeutics by 54.6% during the 1st quarter. MetLife Investment Advisors LLC now owns 18,471 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 6,524 shares in the last quarter. Finally, Knott David M boosted its holdings in shares of Stemline Therapeutics by 1.3% during the 1st quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock valued at $2,028,000 after buying an additional 2,000 shares in the last quarter. 77.66% of the stock is owned by institutional investors and hedge funds.

Shares of STML stock traded up $0.39 on Tuesday, hitting $13.41. The stock had a trading volume of 185,880 shares, compared to its average volume of 376,426. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.07 and a quick ratio of 5.03. The firm has a market capitalization of $585.82 million, a price-to-earnings ratio of -4.48 and a beta of 1.33. Stemline Therapeutics has a 1 year low of $7.82 and a 1 year high of $17.85. The firm has a 50 day moving average of $14.25.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Article: What does cost of debt say about a company’s financial health?

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.